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SCIENTIFIC REPORT
Mitomycin C as an adjunct in the treatment of localised
ocular surface squamous neoplasia
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Aim: To report the outcome of topical mitomycin C (MMC)
used as adjunctive treatment following primary excision of
ocular surface squamous neoplasia (OSSN).
Method: Prospective, non-comparative interventional case
series of 27 primary OSSN lesions from 26 patients treated
in a single ocular oncology centre over a 4 year period.
Result: 27 cases of OSSN received a treatment regimen of
surgical excision, followed by topical MMC. Mean follow up
of 27 (SD 12) months (range 12–50, median 25 months)
revealed zero recurrences.
Conclusion: MMC treatment following surgical excision
decreases the recurrence rate of primary ocular surface
neoplasia and should be considered as adjunctive therapy in
primary treatment.
O
cular surface squamous neoplasia (OSSN) consists of
a spectrum of dysplasia which is relatively common in
clinical ophthalmology practice.1 Primary surgical
excision remains the mainstay of treatment but the recur-
rence rate is high and various adjunctive therapies have been
described.2 Mitomycin C (MMC) has been used in the
treatment of OSSN since 1994.3 MMC has been recom-
mended for treatment of recurrent OSSN.4 5 We present a
series of 27 eyes with localised primary OSSN treated with
surgical excision and adjunctive MMC. The aim of this study
is to report the recurrence rate following treatment of
primary OSSN using adjunctive MMC in a single ocular
oncology centre over a 4 year period.
METHODS
A single centre, prospective, non-comparative, interventional
case series of 27 eyes in 26 patients with primary OSSN was
carried out between November 1998 and February 2003.
Inclusion criteria included histologically confirmed non-
invasive limbal OSSN (with associated corneal involvement)
of less than 4 clock hours in extent. All treatment was carried
out by a single ocular oncologist (JM). All of the lesions were
completely excised superficially from the cornea and limbus
with a 2 mm margin on the conjunctival aspect. Lamellar
dissection was not performed as this increases the risk of
intraocular spread if invasive disease. Double freeze-thaw
cryotherapy with a nitrous oxide cryoprobe was applied to the
superificial limbal base and to the full thickness of the
elevated conjunctival edge. Cryotherapy was not available in
all centres where the treatment was undertaken and there-
fore not used in all cases. Patients were treated with chlora-
mphenicol and Prednefrine Forte eye drops four times daily
until wound healing.
All cases were treated with at least two 1 week courses of
topical MMC 0.04% four times a day, after complete epithelial
healing.6 Each course was followed by 1 week free of MMC.
The patients were examined at 6 monthly intervals. The
primary outcome measure was clinical recurrence of OSSN.
RESULTS
There were 26 patients, seven females and 19 males, with 27
primary OSSN (table 1). The mean age was 64 (SD 13) (range
47–87) years.
Five patients developed granuloma following excision of
OSSN, all of which resolved rapidly with continued topical
steroid treatment. Nineteen patients received three courses of
MMC. Eight patients received two courses because of allergy
to MMC with redness, swelling, and significant itching,
which developed late in the second course. All MMC allergy
symptoms resolved rapidly following discontinuation of
treatment.
All patients have been followed up. The mean follow up
period for the 26 patients was 27 (SD 12) months (range 12–
50 months, median 25 months). There was no evidence of
clinical recurrence in any of these cases.
DISCUSSION
Ocular squamous surface neoplasia (OSSN) is characterised
by a localised, slow growing lesion with low metastatic
potential. Histopathologically, there is a spectrum of intra-
epithelial change before the basement membrane is breached
and invasive squamous cell carcinoma results.1 2
Our study represents the largest series to date of primary
OSSN treated with adjunctive topical MMC. The authors
believe MMC treatment following surgical excision is
effective for local control as attested by the zero recurrence
rate at a mean of 27 months.
Primary excision has been the mainstay of treatment for
OSSN.5 The authors feel that superficial excision remains the
important initial step in management as it is impossible to
exclude invasive disease on clinical grounds or with
impression cytology. Excision allows an immediate histo-
pathological diagnosis, surgical debulking, and excludes life
threatening invasive carcinoma.7 The disadvantage of pri-
mary excision alone is the high recurrence rate which ranges
from 15% to 52%.8 Therefore, numerous adjunctive treat-
ments have been described in an attempt to decrease the rate
of recurrence and the efficacy of various adjunctive therapy
have been debated.
Intraoperative cryotherapy is commonly used as adjunctive
therapy as it is known to decrease the recurrence rate by
destruction of any residual tumour tissue beyond the hori-
zontal or deep surgical margin of the wound.8 In this study,
there is no difference in the overall recurrence rate in those
who received cryotherapy compared with those who did not.
Further randomised controlled trials comparing excision with
MMC versus excision, MMC, and cryotherapy will help deter-
mine the efficacy of cryotherapy in conjunction with MMC.
Mitomycin C is an alkylating agent which acts by
inhibiting DNA synthesis and produces cell death by
apoptosis and necrosis.9 The drug has a preferential action
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for rapidly dividing cells and has significant anti-tumour
activity. Since 1994 several groups have reported the use of
MMC in the treatment of both primary and recurrent
OSSN.10–16 We think that it is unwise to use MMC without
excision biopsy for localised OSSN, as invasive disease may
be undiagnosed and MMC is unlikely to penetrate to the
required level to reach the invasive cells.
MMC allows treatment of the entire ocular surface,
including the conjunctival fornices, and may reach and
destroy subclinical disease and prevent new tumours arising
elsewhere on the ocular surface. Complications of MMC are
common but are largely confined to ocular surface toxicity.
The largest problem with MMC in our series was local allergy
necessitating termination of treatment, as seen in eight cases
(30%). None of our patients experienced significant corneal
epitheliopathy and this may be attributed to the week on,
week off regimen which prevents damage to more slowly
dividing epithelial cells and limbal stem cells, allowing them
to repair their DNA. We believe that allowing time for
complete epithelial healing before application of MMC is
important in avoiding the more serious complications such as
scleral ulceration, uveitis, cataract, and glaucoma.4 10 14 We
noted no systemic side effects as a result of topical MMC
treatment.
In conclusion, our study demonstrates that MMC treat-
ment following surgical excision decreases recurrence rate of
primary ocular surface neoplasia and should be considered as
an adjunctive therapy in primary excision. As there was no
difference in recurrence rate with two courses of MMC, the
authors intend to use only two courses in the future.
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1 56 R Temporal limbal CIN I Granuloma E, MMC 3 Nil 20 No
2 75 L Temporal limbal CIN I E, C, MMC 3 nil 33 No
3 86 R Limbal CIN III E, C, MMC 3 Nil 12 No
4 57 R Nasal limbal CIN I E, MMC 2 Allergy 38 No
5 52 L Nasal limbal CIN II E, C, MMC 3 Nil 40 No
6 57 R Nasal limbal CIN I E, MMC 2 Allergy 36 No
7 57 R Inferonasal limbal CIN I E, C, MMC 2 Allergy 41 No
8 61 R Nasal limbal CIN II E, MMC 2 Allergy 20 No
9 53 R Nasal limbal CIN III Granuloma E, C, MMC 3 Nil 20 No
10 62 R Nasal limbal CIN I Nil E, C, MMC 3 Nil 29 No
11 50 L Nasal limbal CIN III E, C, MMC 3 Itch 7 No
12 53 R Nasal limbal CIN II E, C, MMC 3 Nil 14 No
13 69 R Limbal CIN I E, C, MMC 3 Nil 50 No
14 70 R Nsal CIN II E, MMC 2 Allergy 42 No
15 41 R Temporal limbal CIN I Granuloma E, C, MMC 3 Nil 26 No
16 63 L Temporal CIN III E, C, MMC 2 Allergy 17 No
17 61 R Nasal limbal CIN I E, MMC 2 Allergy 40 No
18 75 L Temporal limbal CIN I Granuloma E, MMC 3 Nil 37 No
19 76 R Limbal CIN I E, MMC 3 Nil 25 No
20 57 L Temporal limbal CIN III E, C, MMC 3 Nil 25 No
21 82 L Temporal limbal CIN III E, C, MMC 3 Nil 20 No
22 49 L Nasal limbal CIN III E, MMC 3 Nil 40 No
23 47 R Nasal CIN II Granuloma E, C, MMC 2 Allergy 23 No
24 73 R Nasal limbal CIN III E, MMC 3 Nil 22 No
25 67 L Temporal CIN I Nil E, C, MMC 3 Nil 24 No
26 87 L Limbal base CIN III E, C, MMC 3 Nil 10 No
27 82 R Limbal CIN I E, C, MMC 3 Nil 13 No
E = excision, C = cryotherapy, MMC = mitomycin C, CIN = conjunctival intra-epithelial neoplasia.
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